TENX
Tenax Therapeutics Inc

16,821
Loading...
Loading...
News
all
press releases
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry...
PR Newswire·10mo ago
News Placeholder
More News
News Placeholder
Tenax Therapeutics, Inc. (NASDAQ:TENX) Short Interest Down 49.4% in March
Tenax Therapeutics, Inc. (NASDAQ:TENX - Get Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling...
Ticker Report·1y ago
News Placeholder
TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips TENX stock results show that Tenax Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. The post...
InvestorPlace·1y ago
News Placeholder
Tenax Therapeutics: Q4 Earnings Insights
read more...
Benzinga·1y ago
News Placeholder
Tenax Therapeutics GAAP EPS of -$31.04
Tenax Therapeutics GAAP EPS of -$31.04...
SeekingAlpha.com: All News·1y ago
News Placeholder
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction...
Globe Newswire·1y ago
News Placeholder
Tenax Therapeutics to Present at the 36th Annual Roth Conference
CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and...
Globe Newswire·1y ago
News Placeholder
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
Dr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data highlighting the use of levosimendan for the treatment of pulmonary hypertension due to heart...
Globe Newswire·2y ago
News Placeholder
Tenax Therapeutics (NASDAQ:TENX) Stock Rating Reaffirmed by Roth Mkm
Tenax Therapeutics (NASDAQ:TENX Get Free Report)s stock had its buy rating reiterated by equities researchers at Roth Mkm in a research report issued to clients and...
Ticker Report·2y ago
News Placeholder
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
Amendment to existing exclusive license agreement with Orion Corporation expands Tenax's territory rights from North America, to the entire worldExpanded rights position Tenax to engage potential...
Globe Newswire·2y ago

Latest TENX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.